- Medicenna Therapeutics Corp. (MDNA) has received another U.S. patent for its MDNA11 and BiSKITs programs
- The U.S. Patent and Trademark Office (USPTO) issued the company the U.S. Patent No. 11,542,312 titled “IL-2 Superagonists in Combination with Anti-PD-1”
- The patent provides intellectual property protection for methods of treating cancer
- Medicenna is a clinical-stage immunotherapy company
- Medicenna Therapeutics was down 5.263 per cent, trading at $0.72 at 1:26 PM ET
Medicenna Therapeutics Corp. (MDNA) has received another U.S. patent for its MDNA11 and BiSKITs programs.
The U.S. Patent and Trademark Office (USPTO) issued the company the U.S. Patent No. 11,542,312 titled “IL-2 Superagonists in Combination with Anti-PD-1.”
The patent provides intellectual property protection for methods of treating cancer with an IL-2 Superkine such as MDNA11 and a PD1 (for example, pembrolizumab), PDL1 or CTLA-4 checkpoint inhibitor in combination, as planned in the ongoing ABILITY clinical trial, or as a single agent using Medicenna’s BiSKIT (Bifunctional SuperKine for ImmunoTherapy) platform.
The patent’s term extends into at least 2039 without accounting for any potential extensions.
“MDNA11 has displayed promising anti-cancer activity during dose escalation in our ABILITY study, and we expect further improvements at the optimal dose in the expansion cohort as well as the combination arm designed to evaluate the synergistic potential of pembrolizumab,” said Dr. Fahar Merchant, President and CEO of Medicenna.
“Whereas checkpoint inhibitors have been shown to benefit less than a third of cancer patients while generating annual sales of over $30B, we believe that combinations with MDNA11 and our BiSKIT platform, as in MDNA223, may significantly improve outcomes and provide hope to cancer patients that do not respond to checkpoint inhibitors,” he added.
MDNA11 is a “beta-only” long-acting IL-2 super-agonist that is being evaluated in patients with advanced solid tumours in the Phase 1/2 ABILITY study. MDNA223 is a preclinical-stage BiSKIT consisting of an anti-PD1 antibody linked to an IL-2 super-agonist (MDNA109FEAA).
MDNA11 and MDNA109FEAA are both designed to selectively stimulate anti-cancer immune cells without activating cells associated with pro-tumour immune pathways or extreme toxicity.
This newly-issued patent adds to Medicenna’s portfolio of issued and filed patents and applications, providing protection for the company’s innovative IL‐2 Superkines, including MDNA11, in the U.S., Europe, Japan, China, Canada, India, and Australia.
The ABILITY (AB eta-only IL-2 Immuno TherapY) study is designed to assess the safety, pharmacokinetics, pharmacodynamics, and anti-tumour activity of various doses of intravenously administered MDNA11 in patients with advanced, relapsed, or refractory solid tumours.
Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines.
Medicenna Therapeutics Corp. was down 5.263 per cent, trading at $0.72 at 1:26 PM ET.